Author:
Procopio G, ,Verzoni E,Bracarda S,Ricci S,Sacco C,Ridolfi L,Porta C,Miceli R,Zilembo N,Bajetta E
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S (2006) A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int J Clin Oncol 11: 434–440
2. Amagai Y, Matsumoto M, Hojo K, Iguchi M, Wada T, Tanaka H, Ide N, Kato A, Shichijo M, Abe K (2010) Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. Jpn J Clin Oncol 40: 503–507
3. 1. Bracarda S, Porta C, Boni C, Santoro A, Artioli F, Contu A, Mentuccia R, Gasparro D, Caserta C, De Angelis V, on behalf of GOIRC study group (2008) Randomized prospective phase 2 trial of two schedules of sorafenib daily and interferon-a2a
4. 2. (IFN) in metastatic renal cell carcinoma (mRCC) (RAPSODY) Pro ASCO GU 2008, abstract 357
5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献